AI Science Tracker

Machine learning-guided cell-free engineering creates specialized amide synthetases for pharmaceutical molecules

Northwestern University; Stanford University · 20 Jan 2025 · biology

Discovery

Machine learning-guided cell-free engineering creates specialized amide synthetases for pharmaceutical molecules

A cell-free design-build-test-learn platform generated sequence-function data from 1,217 McbA variants across 10,953 reactions. Ridge-regression ML guided enzyme variants that produced nine small-molecule pharmaceuticals with activity 1.6- to 42-fold above the parent; initial substrate-promiscuity assays found McbA could make 11 pharmaceutical compounds plus hybrid molecules. This is experimental enzyme engineering, not evidence of therapeutic efficacy of the products.

Technology: Augmented ridge-regression ML models within a cell-free sequence-function mapping and enzyme-engineering workflow

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: A cell-free design-build-test-learn platform generated sequence-function data from 1,217 McbA variants across 10,953 reactions.
  • Still unknown: The platform optimizes in-vitro enzyme production of molecules and does not establish drug efficacy, manufacturing readiness, or broad transferability beyond tested reactions. The nine-product gains are relative to the parent enzyme under the reported assay conditions.
  • AI role: Used measured variant fitness data to predict and select higher-activity McbA variants for distinct amide-forming reactions; selected variants were synthesized and assayed.

Evidence sources: https://www.nature.com/articles/s41467-024-55399-0.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 153 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.